Radiation Therapy for Resectable Colon Cancer

Size: px
Start display at page:

Download "Radiation Therapy for Resectable Colon Cancer"

Transcription

1 Review Article [1] February 01, 2006 By Brian G. Czito, MD [2], Johanna C. Bendell, MD [3], and Christopher G. Willett, MD [4] Colon cancer is a major public health problem. The primary treatment is resection. For patients with early-stage disease, surgery results in excellent survival rates. In contrast, patients with locally advanced tumors arising in "anatomically immobile" segments of large bowel have a less satisfactory outcome, in part secondary to compromised surgical clearance. Patterns-of-failure analyses suggest that for tumors that invade adjacent organs, exhibit perforation or fistula, or are subtotally resected, local failure rates exceed 30%. Multiple single-institution retrospective studies have shown improved local control and possibly survival with the addition of external irradiation and/or intraoperative radiation. In contrast, a recent Intergroup trial failed to show any benefit by the addition of adjuvant radiation therapy combined with chemotherapy. Interpretation of this trial's results is handicapped by low patient accrual. With the advent of novel and more effective systemic therapies for metastatic colon cancer, current and future clinical research will address the efficacy of these agents in the adjuvant setting. Adjuvant radiation therapy should be considered in patients with colon cancer at high risk for local failure. olorectal cancer remains a major worldwide health problem. In the United States alone it is estimated that there will be 145,290 patients diagnosed with colon cancer and 54,200 deaths this year.[1] Worldwide, approximately 1 million new cases per year are diagnosed, with 529,000 deaths.[2] C Most colon cancers arise in the mucosa, and more than 90% are adenocarcinomas. These tumors invade from the mucosa through the bowel wall into surrounding tissues. Lymphatic channel and subsequent lymph node involvement is common. Hematogenous metastases occur primarily in the lung and liver. In contrast to other gastrointestinal malignancies, colon cancer has little propensity to spread longitudinally within the bowel wall. Clinical Manifestation and Staging Colon cancer frequently produces minimal or no symptoms, highlighting the importance of screening programs. Many symptoms related to colon cancer are nonspecific, including changes in bowel habits, intermittent abdominal pain, weakness, and nausea and vomiting. Location of a malignancy within the colon influences clinical presentation. Specifically, right-sided colon cancers are frequently exophytic and may be associated with iron deficiency anemia due to occult blood loss. Over recent decades, the incidence of cancer of the right colon has increased and accounts for approximately one-third of large bowel cancers. Many of these are diagnosed at a later stage. Cancer of the left or sigmoid colon is often deeply invasive, annular, and accompanied by obstructive symptoms and rectal bleeding. For patients with potentially resectable disease, pretreatment evaluation should include colonoscopy to establish pathologic confirmation of adenocarcinoma, to evaluate the extent of tumor, and to detect synchronous primary cancers, which occur in 3% to 5% of patients. Baseline blood counts with liver function tests and carcinoembryonic antigen levels should be obtained. Abdominal and pelvic computed tomography (CT) scan and chest x-ray/chest CT scan allow for evaluation of the extent of locoregional disease as well as the presence or absence of distant metastases. Positron-emission tomography, magnetic resonance imaging, and ultrasound may be useful in evaluating patients with oligometastatic disease who may be appropriate candidates for resection of distant metastases with curative intent. Figure 1 shows a diagnostic algorithm for the management of patients with potentially resectable colon cancer. Prognostic factors influencing survival in colon cancer patients include depth of tumor invasion into and beyond the bowel wall, the number of involved regional nodes, and the presence or absence of distant metastases. These factors are included in the tumor-node-metastasis (TNM) system of the American Joint Committee on Cancer (AJCC), which can be used as a clinical (preoperative) or postoperative staging system (Tables 1 and 2).[3] Surgery Surgery remains the primary treatment for patients with colon cancer. Approximately 75% of Page 1 of 12

2 patients are candidates for resection at presentation. Surgical technique is based on large bowel anatomy and patterns of disease spread. Adenocarcinomas generally grow by direct extension into the bowel wall and submucosal lymphatics. Resection of sufficient lengths of bowel proximally and distally to the primary cancer avoids cutting across intramural lymphatics. Resection generally includes removal of the mesentery, where the major lymphatic drainage is located. The boundaries for resection of large bowel cancers are relatively uniform and include named blood vessels along with their associated draining lymphatics (Figure 2). In patients with disease limited to the bowel wall without involved nodes, resection provides excellent cure rates (5-year survival rate of 97% for T1, N0; 85%-90% for T2, N0). When disease extends beyond the colonic wall (T3-4, N0) or involves locoregional lymph nodes (T0-2, N1-2), 5-year survival with surgery falls to approximately 65% to 75%. Adjuvant treatment is often indicated in these patients. For higher-risk patients with extension beyond the colonic wall and nodal involvement (T3-4, N1-2), 5-year survival ranges from 35% to 50% and adjuvant treatment is strongly recommended. Adjuvant Chemotherapy Fluorouracil/Leucovorin For more than a decade, fluorouracil (5-FU)-based chemotherapy has been considered standard adjuvant therapy for stage III colorectal cancer. Three major clinical trials defined the use of 5-FU/leucovorin chemotherapy as the standard of care for these patients. The first of these trials was National Surgical Adjuvant Breast and Bowel Project (NSABP) C-03, which randomized 1,081 patients Page 2 of 12

3 with resected Dukes B and C colon cancer to either a regimen known as MOF (methyl-lomustine [CCNU, CeeNU], vincristine [Oncovin], 5-FU) or 5-FU/leucovorin.[4] This trial showed a significant increase in 3-year disease-free survival (73% vs 64%) and overall survival (84% vs 77%) for the 5-FU/leucovorin group. The IMPACT report pooled data from 1,526 patients with resected Dukes B or C colon cancer who were treated on one of three randomized clinical trials from Canada, Italy, and France. Patients were randomized to 5-FU and leucovorin given as a daily bolus on days 1 to 5 of a monthly cycle for 6 months, or observation. The 3-year overall survival rate was superior for the treated group (83% vs 78%), translating to a 22% reduction in mortality.[5] The North Central Cancer Treatment Group (NCCTG) randomized 317 patients with resected high-risk stage II or III disease to bolus 5-FU and leucovorin delivered as the Mayo Clinic regimen (bolus 5-FU, 425 mg/m2, and leucovorin, 20 mg/m2, given on days 1 to 5 of a 28-day cycle) or observation.[6,7] Treated patients showed a statistically significant improvement in overall survival. Oxaliplatin Recently, newer chemotherapy agents demonstrating benefit in patients with metastatic disease have been tested in the adjuvant setting. The benefit of oxaliplatin (Eloxatin) in the metastatic setting was shown by Goldberg et al in the Intergroup 9741 study. This trial randomized 795 patients with metastatic colorectal cancer to IFL (irinotecan [Camptosar], 5-FU, leucovorin), FOLFOX4 (a regimen of infusional 5-FU/leucovorin with oxaliplatin chemotherapy), or IROX (irinotecan, oxaliplatin). Compared to patients receiving IFL or IROX, patients receiving FOLFOX experienced an improved median survival (19.5 vs 15 vs 17.4 months; P <.05 for oxaliplatin vs non-oxaliplatin-containing regimens).[8] In the adjuvant setting, the MOSAIC study demonstrated the benefit of oxaliplatin. This trial randomized 2,246 patients with resected stage II/III colon cancer to FOLFOX4 or the same infusional 5-FU/leucovorin regimen alone.[9] The 3-year disease-free survival in the FOLFOX4 group was significantly improved with the addition of oxaliplatin (78.2% vs 72.9%). The beneficial role for oxaliplatin in the adjuvant setting was further confirmed with the results of NSABP C-07. This trial randomized 2,407 patients with resected stage II/III colon cancer to bolus 5-FU and leucovorin (5-FU, 500 mg/m2, and leucovorin, 500 mg/m2, given weekly for 6 out of 8 weeks for three cycles) or the same bolus 5-FU/leucovorin regimen plus oxaliplatin at 85 mg/m2 on weeks 1, 3, and 5 of each cycle.[10] The addition to oxaliplatin resulted in a significant improvement in 3-year disease-free survival (76.5% vs 71.6%), similar to the MOSAIC study. Irinotecan Irinotecan, a topoisomerase I inhibitor, has also been shown to improve survival when combined with 5-FU and leucovorin in the metastatic setting. Saltz et al reported a randomized trial comparing IFL, 5-FU/leucovorin, and irinotecan alone. Patients receiving IFL had an improved median survival and response rate compared to 5-FU/leucovorin alone (14.8 vs 12.6 months, 39% vs 21%, respectively, P <.05).[11] As with oxaliplatin, adjuvant trials have been reported using irinotecan in combination with 5-FU and leucovorin. However, these trials have not confirmed benefit. The first reported phase III trial of this combination was CALGB 89803, which randomized 1,264 patients with resected stage III disease to bolus irinotecan, 5-FU, and leucovorin or 5-FU/leucovorin alone.[12] No significant difference in disease-free or overall survival was observed. In addition, patients receiving irinotecan had a significantly higher mortality rate during treatment (2.8% vs 1.0%), prompting premature closure of the trial. The PETACC 3 study examined the use of irinotecan with an infusional 5-FU/leucovorin regimen. These investigators randomized 3,278 patients with resected stage II or stage III colon cancer to one of two infusional 5-FU/leucovorin regimens with irinotecan.[13] Patients with stage III disease showed no statistically significant improvement in 3-year disease-free survival with the addition of irinotecan. Pooled data including stage II patients showed a significant (although marginal) benefit for disease-free survival (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = ). Capecitabine Capecitabine (Xeloda), an oral fluoropyrimidine, was compared to 5-FU/leucovorin bolus chemotherapy in the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial. Investigators randomized 1,987 patients with resected Dukes C colon cancer to capecitabine or bolus 5-FU and leucovorin given on days 1 to 5 of a 28-day cycle for 24 weeks.[14] Disease-free and overall survival rates were comparable in the two arms, with a nonsignificant trend toward improved disease-free and overall survival in the capecitabine arm. Despite recent improvements in chemotherapy, patterns-of-recurrence analyses suggest that 5-FU-based therapy has only minimal efficacy in Page 3 of 12

4 preventing local recurrence in resected stage III disease, and local failure rates may be similar to those in patients undergoing surgery alone.[15,16] Targeted Therapies The current focus in adjuvant therapy for colon cancer involves the incorporation of targeted therapies. In 2003, Hurwitz et al first reported the results of a randomized trial comparing IFL with or without bevacizumab (Avastin), a monoclonal antibody directed against vascular endothelial growth factor.[17] Median survival was significantly improved in patients receiving bevacizumab (20.3 vs 15.6 months, P <.001). Additionally, patients receiving bevacizumab demonstrated improved response rates (45% vs 36%, P <.05). The first of the trials evaluating the addition of bevacizumab in the adjuvant setting is MOSAIC-2, or AVANT, which is being conducted in Europe. This trial is randomizing patients with resected stage II or III colon cancer to FOLFOX4, FOLFOX4 plus bevacizumab, or a regimen of capecitabine, oxaliplatin, and bevacizumab. A similar trial is enrolling patients in the United States through the National Cancer Institute and Roche Pharmaceuticals. Additionally, the NSABP C-08 is currently randomizing patients with resected high-risk stage II or III colon cancer to modified FOLFOX6 (another regimen of infusional 5-FU, leucovorin, oxaliplatin) vs FOLFOX6 plus bevacizumab. Patients randomized to the bevacizumab arm will then receive bevacizumab alone for 6 months after completion of chemotherapy. Cetuximab (Erbitux), a monoclonal antibody targeting the epidermal growth factor receptor, has also shown benefit in patients with metastatic colorectal cancer. Cunningham et al described 329 patients with irinotecan-refractory colorectal cancer who received cetuximab alone or cetuximab with irinotecan. Response rates and median time to progression were significantly improved in Page 4 of 12

5 patients receiving combination therapy, although no survival difference was observed.[18] The NCCTG is currently randomizing patients with resected stage III colon cancer to infusional 5-FU/-leucovorin and oxaliplatin, infusional 5-FU/leucovorin and irinotecan, infusional 5-FU/leucovorin and oxaliplatin followed by infusional 5-FU/leucovorin and irinotecan, or these regimens plus cetuximab. The role of targeted therapies in the adjuvant treatment of colon cancer remains an area of active investigation. Adjuvant Radiation Therapy Patterns of Relapse With Surgery Alone In contrast to chemotherapeutic regimens, there has been little systematic evaluation of adjuvant radiation therapy for patients with resected colon cancer. This is likely due to the documented efficacy of adjuvant chemotherapy as well as the perception by many oncologists that colonic (as opposed to rectal) cancer is much more likely to relapse distantly vs locally. Increasing TNM stage predicts for local failure in both colon and rectal cancers; however, local failure in colon cancer is dependent on anatomic location. The ascending and descending colon are considered "anatomically immobile" structures. The close proximity of these bowel segments to retroperitoneal tissues often precludes wide surgical resection (Figure 3).[19] These relationships may limit the ability of the surgeon to obtain adequate radial margins at resection, thus increasing the risk of residual disease and subsequent local failure. In contrast, the midsigmoid and midtransverse colon are more "mobile" structures, where obtaining wide margins in the mesentery is often achievable. In the absence of adjacent organ adherence, local failure at these sites is uncommon. Local failure rates in the cecum, hepatic and splenic flexure, as well as proximal and distal sigmoid tumors vary depending on the amount of mesentery present, extent of primary disease, and adequacy of radial margins. Clinical Trials Nonrandomized Series Until recently, data evaluating adjuvant radiation therapy in the setting of high-risk colon cancer was limited to single-institution retrospective analyses.[20-24] In summary, these studies suggested that failure rates within the operative bed in high-risk patients undergoing resection alone were at least 30%, and that this risk was reduced by the administration of adjuvant radiation therapy. These studies are discussed in detail below. University of Minnesota Reoperation Series Gunderson et al reported a series of 91 patients with colon cancer undergoing resection for locally advanced disease. At 6 to 12 months following the initial surgery, reoperation (the so-called "second look") was carried out in patients without evidence of recurrence. The underlying rationale was to define the location of subclinical failures at a time when additional operative excision and cure might be possible. Most (87/91) patients had T3 and/or node-positive disease at initial resection. Approximately half Page 5 of 12

6 of the patients had disease in segments of colon with a complete or nearly complete mesentery (ie, the "anatomically mobile" transverse colon or "semimobile" cecum) and the remainder, in "immobile" locations (ascending, descending, and hepatic/splenic flexure). At reexploration, a total of 44 (48%) were found to have locoregional failure. In node-positive patients, increasing depth of penetration of the bowel wall predicted for increasing risk of locoregional failure. When assessed by colonic subsite, all patients had a risk of locoregional failure > 40% except those with transverse (38%) and ascending (29%) lesions. The lower risk of locoregional failure in the "anatomically immobile" ascending colon was attributed to a disproportionate percentage of early T-stage lesions. The authors concluded that (1) locoregional failure in resected colon cancer is common, (2) patterns-of-failure analyses using imaging, as compared to reoperation or autopsy, likely underestimate the incidence of locoregional recurrence, (3) similar to what is seen in rectal cancer, locoregional recurrence is a major cause of failure in advanced colon cancer, and (4) certain high-risk patients may benefit from adjuvant radiation therapy.[20] Massachusetts General Hospital A series from the Massachusetts General Hospital (MGH) evaluated outcomes in high-risk colon cancer patients undergoing resection followed by adjuvant radiation therapy and compared these to a historical series treated by resection alone. Irradiated patients included T4, N0/+; T3, N+ (excluding midsigmoid and midtransverse colon); and selected high-risk T3, N0 patients. A total of 171 patients received postoperative irradiation, with 63 patients receiving concurrent chemotherapy (usually 5-FU, 500 mg/m2/d on days 1-3 during the first and last week of radiation therapy). Radiation therapy was administered through a multifield approach, Page 6 of 12

7 including treatment of the tumor bed with a 3- to 5-cm margin to 45 Gy. Thereafter, reduced fields were used to bring the total dose to Gy. Draining nodes were included if patients were deemed to be at high risk for involvement. The irradiated cohort was compared to 395 patients of similar T and N stage undergoing surgery alone. Table 3 shows 5-year actuarial local control and relapse-free survival in patients receiving adjuvant treatment compared to surgery alone. Local failure rates in T4, N0 and T4, N+ patients treated with radiation therapy were 7% and 28%, respectively, compared to 31% and 53%, respectively, in patients undergoing surgery alone. Similarly, disease-free survival rates were 79% and 53%, respectively, in T4, N0 and T4, N+ patients receiving adjuvant radiation vs 63% and 38%, respectively, in patients undergoing surgery alone. No significant outcome differences were seen in patients with T3, N0 or T3, N+ disease. However, many of these patients were referred secondary to concerns about adequacy of resection and local control after resection, raising the possibility of selection bias. A nonsignificant trend toward improved local control was seen in patients receiving 5-FU. The authors concluded that patients with T4 tumors, tumors with abscess/fistula formation or margin-positive resection may benefit from postoperative irradiation.[21] Follow-up analysis from the MGH evaluated 152 patients with T4 disease receiving adjuvant radiation therapy. Of these patients, 28% underwent margin-positive resection. In patients undergoing margin-negative resection, the 10-year actuarial local control in T4, N0 and T4, N+ was 87% and 65%, respectively. In patients with node-negative tumors, the 10-year actuarial relapse-free survival rate was 58%, compared to 33% in patients with node positive tumors. For patients with one involved lymph node, local control and relapse-free survival were similar to that seen in patients without nodal involvement. However, increasing nodal number correlated with decreasing survival.[22] Mayo Clinic Investigators from the Mayo Clinic reported on 103 patients receiving radiation therapy following resection of locally advanced colon cancer. Microscopic (R1) and gross residual (R2) resection were noted in 18 and 35 patients, respectively. Over 90% of patients had T4, N0/N+ disease. Patients received 50.4 Gy of external-beam irradiation given through a multifield technique. Most received concurrent 5-FU-based chemotherapy. Eleven patients received an intraoperative irradiation "boost" of 10 to 20 Gy. The overall local control rate was 40%. Patients undergoing margin-negative resection had a 5-year local control rate of 90%; patients with microscopic or gross residual disease following resection had local control rates of 46% and 21%, respectively (Figure 4). In patients with R1/R2 resection undergoing intraoperative irradiation, local control was 89%, compared to 18% in patients receiving external irradiation alone (P =.02). Similarly, 5-year survival was improved in patients undergoing margin-negative resection compared to R1 or R2 resection (66% vs 47% vs 23%, respectively). Patients receiving the intraoperative boost experienced improved 5-year survival (76% vs 26%, P =.04).[23] Page 7 of 12

8 University of Florida Investigators from the University of Florida described 78 patients with locally advanced but completely resected colon cancer receiving adjuvant radiation. The overall local control rate was 88%. These figures are similar to the 90% local control rate reported by the Mayo Clinic investigators in patients undergoing R0 resection. Additionally, these investigators reported on a possible dose-response relationship to local control, with patients receiving greater than or equal to 50 Gy experiencing a 5-year local control rate of 96% vs 76% for patients receiving less than 50 Gy (P =.01).[24] Randomized Phase III Trial Based on the above studies, the Intergroup undertook a randomized phase III trial to assess whether the addition of radiation therapy to adjuvant chemotherapy improved survival and locoregional failure rates in resected high-risk colon cancer patients. Eligibility criteria included patients with T4 tumors undergoing margin-negative resection (excluding peritoneal invasion) or T3, N+ tumors arising in the ascending or descending colon. Patients were randomized to receive weekly 5-FU combined with levamisole (Ergamisol) for 12 months or 5-FU and levamisole for 12 months with concurrent radiation starting 1 month after the first 5-FU administration. Patients received 45 Gy at 1.8 Gy per fraction over 5 weeks with an optional 5.4-Gy boost. The initial accrual goal of this trial was 700 patients. However, between 1992 and 1996, only 222 patients were entered, with 189 evaluable. Therefore, total accrual was approximately one-third of the initially intended goal, significantly decreasing the study's statistical power to detect differences between the two groups. That said, no difference in overall or disease-free survival was observed. Patients receiving chemotherapy alone experienced a 5-year survival of 62%, compared to 58% in patients randomized to chemoradiation (P >.50). There were 18 local recurrences in each arm. Grade 3/4 hematologic toxicity was higher in patients receiving radiation therapy.[25] Because of the study's decreased statistical power, no definitive conclusions could be made regarding the efficacy (or lack thereof) of postoperative irradiation and chemotherapy. Adjuvant Hepatic and Whole-Abdominal Irradiation Patterns-of-failure analyses have demonstrated that, in addition to local failure, development of hepatic metastases is a common mode of failure in patients with stage III colon cancer. Based on Page 8 of 12

9 such findings, investigators have examined the role of hepatic irradiation following resection in high-risk patients. A prospective trial performed by the Gastrointestinal Tumor Study Group (GITSG) randomized 300 patients with resected T3-4, N0-N+ colon cancer to observation only or adjuvant hepatic irradiation concurrent with bolus 5-FU administered during week 1. Patients received 1.5 Gy daily to the liver, to a total dose of 21 Gy. Patients receiving radiation went on to receive additional 5-FU following completion. Results of this study showed no improvement in overall or disease-free survival with the addition of radiation therapy and 5-FU.[26] In addition to locoregional and hepatic recurrence, relapse within the peritoneal cavity remains a common mode of failure in patients with locally advanced colon cancer. Based on this tendency, investigators from the Southwest Oncology Group (SWOG) performed a pilot study in 41 patients with resected T3, N+, M0 colon cancer. Patients received continuous-infusion 5-FU (200 mg/m2/d) with concomitant whole-abdominal irradiation. Radiation was given at 1 Gy per fraction daily to a total of 30 Gy, followed by a 16-Gy boost to the tumor bed. Patients then received further 5-FU therapy. Five-year disease-free and overall survival rates were 58% and 67%, respectively. In patients with more than four involved lymph nodes, 5-year disease-free and overall survivals were 55% and 74%, respectively. Grade 3 and 4 toxicity was seen in 17% and 7% of patients, respectively. Compared to matched-stage patients from prior Intergroup trials treated with 5-FU/levamisole alone, these results appeared favorable. The investigators concluded that a randomized trial evaluating continuous-infusion 5-FU and whole-abdominal irradiation with boost should be carried out.[27] With the multitude of new and novel agents approved for use in metastatic colorectal cancer, present and future clinical research will be focused on assessing the efficacy of these agents. As previously mentioned, integrating these agents in the adjuvant setting for patients with resected stage II/III disease in the cooperative group trial networks is a high priority. Recommendations Because the role of adjuvant radiation therapy in colon cancer remains undefined and unlikely to be further evaluated in a definitive randomized trial, treatment recommendations should be made on a case-by-case basis with the previously discussed data. The risks, benefits, and potential side effects of such an approach should be discussed with patients in the setting of an informed consent. Table 4 presents general treatment recommendations for appropriate patients, reflecting the preferences of the authors of this review. The use of intraoperative irradiation in addition to external irradiation in patients with uncertain margins at resection (ie, T4 disease) may also be appropriate. In these situations, a potential treatment sequence would consist of preoperative external irradiation with 5-FU-based chemotherapy, followed by resection with intraoperative irradiation where appropriate. This would be followed by adjuvant systemic therapy. A similar approach would be indicated for patients with locally recurrent colorectal cancer or regional nodal relapse. Our current practice is to offer adjuvant tumor bed irradiation in patients with tumors invading adjoining structures (T4 disease), disease complicated by perforation or fistula, or subtotal resection. Patients are generally given continuous-infusion 5-FU (225 mg/m2/d) 5 days per week throughout the course of radiation therapy. Page 9 of 12

10 Conclusions The role of adjuvant radiation in colon cancer remains ill-defined. Surgery remains the primary treatment for cure in these patients; patterns-of-failure data suggest that subsets of patients undergoing resection alone have a risk of local failure greater than or equal to 30% (ie, T4 disease, disease complicated by perforation or fistula, and patients undergoing incomplete excision). Retrospective series have suggested that the addition of adjuvant radiation therapy with concurrent chemotherapy may decrease the risk of local failure in these patients. However, an Intergroup randomized trial comparing chemotherapy to chemoradiation showed no obvious benefit with the addition of radiation; this trial failed to meet accrual goals, and thus, interpretation is hampered. With the advent of improved systemic therapies, it is unlikely that this question will ever be definitively answered in a randomized setting. Therefore, treatment recommendations on the use of radiation should be made on a case-by-case basis, identifying patients at high risk for local failure. Disclosures: Dr. Czito receives research funding from Roche, Sanofi-Aventis, and Genentech. Dr. Bendell is a consultant for Genentech. References: 1. Jemal A, Murray T, Ward E, et al: Cancer statistics, CA Cancer J Clin 55:10-30, Parkin D, Bray F, Ferlay J, et al: Global cancer statistics, CA Cancer J Clin 55:74-108, Colon and rectum, in American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th ed, pp New York, Springer, Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: , Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: , Moertel C, Fleming T, MacDonald J, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: , O Connell M, Mailliard J, Kahn M, et al: Controlled trial of 5-FU and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: , Goldberg R, Sargent D, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: , Wolmark N, Wieland HS, Kuebler JP, et al: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or stage III carcinoma of the colon: Results of NSABP protocol C-07 (late-breaking abstract 3500). J Clin Oncol 23(16S):1092s, Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: , Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803) (abstract 3500). Proc Am Soc Clin Oncol 23:246, Van Cutsem E, Labianca R, Hossfeld D, et al: Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients Page 10 of 12

11 (pts) (PETACC 3) (late-breaking abstract 8). J Clin Oncol 23(16S):1090s, Cassidy J, Scheithauer W, McKendrick J, et al: Capecitabine (X) versus bolus 5-FU/LV as adjuvant therapy for colon cancer (the X-ACT study): Positive efficacy results of a phase III trial (abstract 3509). J Clin Oncol 22(14S), Moertel C, Fleming T, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: , Estes N, Giri S, Fabian C: Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy. Am Surg 62: , Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: , Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: , Gunderson LL, O Connell MJ: The postoperative chemotherapy/irradiation adjuvant strategy, in Cohen AF, Winawer SJ, Friedman MA, et al (eds): Cancer of the Colon, Rectum, and Anus, chap 67, pp New York, McGraw-Hill, Inc, Gunderson L, Sosin H, Levitt S: Extrapelvic colon-areas of failure in a reoperative series: Implications for adjuvant therapy. Int J Rad Oncol Rad Bio 11: , Willett C, Fung C, Kaufman D, et al: Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol 11: , Willett C, Goldberg S, Shellito P, et al: Does postoperative radiation play a role in the adjuvant therapy of stage T4 colon cancer? Cancer J Sci Am 5: , Gunderson L, Nelson T, Martenson J, et al: Locally advanced primary colorectal cancer. Intraoperative electron and external beam irradiation +/- 5-FU. Int J Radiat Oncol Biol Phys 37: , Amos E, Mendenhall W, McCarty P, et al: Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol 3: , Martenson J, Willett C, Sargent D, et al: A phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: Results of Intergroup protocol J Clin Oncol 22, , Gastrointestinal Tumor Study Group: Adjuvant therapy with hepatic irradiation plus 5-FU in colon carcinoma. Int J Radiat Oncol Biol Phys 21: , Fabian C, Giri S, Estes N, et al: Adjuvant continuous infusion 5-FU, whole abdominal radiation and tumor bed boost in high-risk stage III colon carcinoma: A Southwest Oncology Group pilot study. Int J Radiat Oncol Biol Phys 32: , Source URL: Links: [1] [2] [3] [4] Page 11 of 12

12 Page 12 of 12

Current Status of Adjuvant Therapy for Colorectal Cancer

Current Status of Adjuvant Therapy for Colorectal Cancer Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas

More information

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND

More information

Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital

Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for

More information

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,

More information

Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer

Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant

More information

Management of Advanced Colorectal Cancer in Older Patients

Management of Advanced Colorectal Cancer in Older Patients Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information

Northwestern University, Division of Hematology/Oncology, Chicago, Illinois, USA. Key Words. Colon cancer Stage II Adjuvant chemotherapy

Northwestern University, Division of Hematology/Oncology, Chicago, Illinois, USA. Key Words. Colon cancer Stage II Adjuvant chemotherapy The Oncologist Dialogues in Oncology Adjuvant Therapy in Stage II Colon Cancer: Current Approaches LISA BADDI, AL BENSON III Northwestern University, Division of Hematology/Oncology, Chicago, Illinois,

More information

Stage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007

Stage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer

More information

Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From

Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,

More information

Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer

Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage

More information

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information

Adjuvant therapy in colon cancer: which treatment in 2005?

Adjuvant therapy in colon cancer: which treatment in 2005? Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of

More information

11/21/13 CEA: 1.7 WNL

11/21/13 CEA: 1.7 WNL Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.

More information

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif

More information

COLORECTAL CANCER 44

COLORECTAL CANCER 44 COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,

More information

Locally Advanced Colon Cancer. Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery

Locally Advanced Colon Cancer. Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery Locally Advanced Colon Cancer Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery Case 34 yo man presented with severe RLQ abdominal pain X 24 hrs. No nausea/vomiting/fever. + flatus.

More information

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W 癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin

More information

RECTAL CANCER CLINICAL CASE PRESENTATION

RECTAL CANCER CLINICAL CASE PRESENTATION RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare

More information

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14 Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related

More information

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive

More information

Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early

More information

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev

More information

ADJUVANT CHEMOTHERAPY...

ADJUVANT CHEMOTHERAPY... Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED

More information

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,

More information

Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens

Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens Original Article Journal of the Korean Society of J Korean Soc Coloproctol 2012;28(5):259-264 http://dx.doi.org/10.3393/jksc.2012.28.5.259 pissn 2093-7822 eissn 2093-7830 Oncologic Outcomes of Stage IIIA

More information

Colon, Rectum, and Appendix

Colon, Rectum, and Appendix Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline

More information

Colon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics

Colon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline

More information

Impact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer

Impact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer Impact of in Patients With Curatively Resected Stage IV Colorectal Cancer Hirotoshi Kobayashi, MD, FACS, Kenjiro Kotake, MD, and Kenichi Sugihara, MD, Study Group for Peritoneal Metastasis from Colorectal

More information

Adjuvant treatment Colon Cancer

Adjuvant treatment Colon Cancer ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant

More information

Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma

Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma 1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.

More information

Adjuvant/neoadjuvant systemic treatment of colorectal cancer

Adjuvant/neoadjuvant systemic treatment of colorectal cancer 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico

More information

Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma

Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective

More information

療指引 34 Adjuvant Therapy of Colon Cancer

療指引 34 Adjuvant Therapy of Colon Cancer 療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine

More information

Kaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi

Kaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid

More information

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools - Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Rectal Cancer: Classic Hits

Rectal Cancer: Classic Hits Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic

More information

Follow this and additional works at: Part of the Neoplasms Commons

Follow this and additional works at:   Part of the Neoplasms Commons Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Will the Addition of Oxaliplatin to 5-Fluorouracil

More information

Carcinoma del retto: Highlights

Carcinoma del retto: Highlights Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau

More information

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:

More information

Imaging in gastric cancer

Imaging in gastric cancer Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.

More information

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered

More information

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D. Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation

More information

IMAGING GUIDELINES - COLORECTAL CANCER

IMAGING GUIDELINES - COLORECTAL CANCER IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and

More information

CHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012

CHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012 CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of

More information

Therapy for Metastatic Colorectal Cancer

Therapy for Metastatic Colorectal Cancer Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key

More information

Colon, or Colorectal, Cancer Information

Colon, or Colorectal, Cancer Information Colon, or Colorectal, Cancer Information Definition Colon, or colorectal, cancer is cancer that starts in the large intestine (colon) or the rectum (end of the colon). Other types of cancer can affect

More information

A916: rectum: adenocarcinoma

A916: rectum: adenocarcinoma General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these

More information

COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE

COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk

More information

How much colon should be resected?

How much colon should be resected? Colon Cancer Surgical Standard of Care and Operative Techniques Madhulika G. Varma MD Professor and Chief Section of Colorectal Surgery University of California, San Francisco How much colon should be

More information

Treatment strategy of metastatic rectal cancer

Treatment strategy of metastatic rectal cancer 35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent

More information

Adjuvant Chemotherapy for Stage II Colon Cancer

Adjuvant Chemotherapy for Stage II Colon Cancer March 01, 2008 By Scott Kopetz, MD [1], Daniela Freitas, MD [2], Aknar F. C. Calabrich, MD [3], and Paulo M. Hoff, MD, FACP [4] Adjuvant therapy is defined as any treatment administered after surgical

More information

Treatment of Locally Advanced Rectal Cancer: Current Concepts

Treatment of Locally Advanced Rectal Cancer: Current Concepts Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

ADJUVANT AND NEOADJUVANT MANAGEMENT OF COLORECTAL CANCER

ADJUVANT AND NEOADJUVANT MANAGEMENT OF COLORECTAL CANCER gastrointestinal tract and abdomen ADJUVANT AND NEOADJUVANT MANAGEMENT OF COLORECTAL CANCER Christina E. Bailey, MD, MSCI, Eduardo Vilar, MD, PhD, and Y. Nancy You, MD, MHSc In 2013, colorectal cancer

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our

More information

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c

More information

Adjuvant Treatment of Colorectal Cancer

Adjuvant Treatment of Colorectal Cancer Adjuvant Treatment of Colorectal Cancer Adjuvant Treatment of Colorectal Cancer Brian M. Wolpin, MD; Jeffrey A. Meyerhardt, MD, MPH; Harvey J. Mamon, MD, PhD; Robert J. Mayer, MD Dr. Wolpin is Instructor

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

Radiation Oncology MOC Study Guide

Radiation Oncology MOC Study Guide Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)

More information

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large

More information

Department of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India

Department of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach

A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun

More information

2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?

2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer? Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Update on Chemotherapy for Advanced Colorectal Cancer

Update on Chemotherapy for Advanced Colorectal Cancer Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have

More information

COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE

COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.;

More information

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日 大腸直腸癌 抗癌藥物治療指 討論日期 團隊討論 : 05 年 0 月 9 日 三院討論 : 05 年 2 月 7 日 團隊確認 : 06 年 月 25 日 核備日期 : 06 年 4 月 8 日 Adjuvant Therapy of Colon Cancer mfolfox6 參考文獻 -3 Oxaliplatin 85 Q2W 2 Leucovorin 400 Q2W 2 5-FU 400 Q2W

More information

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m

More information

NCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17

NCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17 Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.

More information

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details

More information

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery

More information

COLORECTAL CANCER CASES

COLORECTAL CANCER CASES COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant

More information

The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer

The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer Turkish Journal of Cancer Volume 38, No. 4, 28 175 The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer ABDULLAH BÜYÜKÇELİK

More information

ANTICANCER RESEARCH 26: (2006)

ANTICANCER RESEARCH 26: (2006) Clinical Impact of Adjuvant Chemotherapy on Patients with Stage III Colorectal Cancer: l-lv/5fu Chemotherapy as a Modified RPMI Regimen is an Independent Prognostic Factor for Survival TSUKASA HOTTA, KATSUNARI

More information

CLINICAL INVESTIGATION

CLINICAL INVESTIGATION Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal

More information

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection Original article Annals of Oncology 15: 568 573, 2004 DOI: 10.1093/annonc/mdh134 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after

More information

COLON AND RECTAL CANCER

COLON AND RECTAL CANCER No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux. Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately

More information

Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference

Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Jpn J Clin Oncol 2010;40(Supplement 1)i38 i43 doi:10.1093/jjco/hyq125

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

Prognostic Significance of Perineural Invasion in Patients with Rectal Cancer using R Environment for Statistical Computing and Graphics

Prognostic Significance of Perineural Invasion in Patients with Rectal Cancer using R Environment for Statistical Computing and Graphics [ Applied Medical Informatics Original Research Vol. 31, No. /2012, pp: 13-20 Prognostic Significance of Perineural Invasion in Patients with Rectal Cancer using R Environment for Statistical Computing

More information

COLON AND RECTAL CANCER

COLON AND RECTAL CANCER COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal

More information

By: Tania Cortas, MD Arizona Oncology 03/10/2015

By: Tania Cortas, MD Arizona Oncology 03/10/2015 By: Tania Cortas, MD Arizona Oncology 03/10/2015 Epidemiology In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years Death rates from CRC have declined

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Long Term Outcomes of Preoperative versus

Long Term Outcomes of Preoperative versus RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn

More information

CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION

CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING

More information